Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

The purpose of this study is to test the safety of using T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (CAR.B7-H3T cells) in patients with glioblastoma. CAR.B7-H3T cells treatment has not been tested in humans and is not an approved treatment by the Food and Drug Administration for glioblastoma.

Trial Details

NCT ID

NCT05366179

Phase

PHASE1

Sponsor

UNC Lineberger Comprehensive Cancer Center

Status

RECRUITING

Cancer Type

Glioblastoma (GBM) Brain Cancer

Interventions

CAR.B7-H3T cells infusion

Locations (sample)

Chapel Hill, North Carolina, United States|35.9132,-79.05584

Key Eligibility Criteria

Karnofsky score of \> 60%
Diagnosis or recurrent supratentorial- or infra-tentorial glioblastoma multiforme (GBM) (World Health Organization 2016 or 2021) based on Response …
Must have undergone at least 4005 cGy of radiation with concurrent temozolomide.
No current or previous exposure to antiangiogenic agents, such as bevacizumab.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →